Targeted antibodies directed to DLL4
US8192738B2 · kind B2 · utility
13Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 18, 2009 |
| Grant date | Jun 5, 2012 |
| Priority date | — |
| Expiry date | May 3, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.